Trial Profile
Phase II Trial of Maintenance Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms PROMPT
- 27 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 17 Mar 2022 Planned End Date changed from 17 Mar 2024 to 17 Mar 2025.
- 17 Mar 2022 Planned primary completion date changed from 17 Mar 2024 to 17 Mar 2025.